CAR-T research: The essentials

In the following article Creative Biolabs introduces its products for CAR-T therapy research and development as an active response to recent headlines pointing to the success of CAR-T therapies in treating blood cancers, such as leukaemia and lymphoma.

In the world of oncology, few innovations have made as profound an impact as CAR-T cell therapy, which, comparable in significance to mRNA technology as of COVID-19, has revolutionised the way research communities approach cancer therapy, offering new hope to patients with aggressive and treatment-resistant cancers. Creative Biolabs claims to be at the forefront of this revolution, providing CAR-T therapy services and products that empower researchers and pharmaceutical companies to advance their projects and develop life-saving therapies.

CAR Cell Products: The Cornerstone

CAR engineered T cells have remarkably achieved inspiring outcomes in patients with B cell malignancies and are now under intensive investigation in other hematologic malignancies and solid tumors. Catering to climbing research needs, Creative Biolabs provides assorted CAR cell products that are characterised by high specificity, robust activity, and superior safety profiles, including:


- CAR-γδ T Cells
- CAR-CIK Cells
- CAR-iT Cells
- CAR-Treg Cells
- CAR Jurkat Cells
- TSCM CAR-T Cells
- CAR Animal Cells
- CAR-MA Cells

"Our cells have access to authentication, which is of vital importance to ensure the reliability of any research results. We follow the highest manufacturing standards and use the most reliable processes and quality controls to verify and authenticate every cell line." According to a scientist at Creative Biolabs.

TCR Cell Products: The Nexus

TCR-T cells, potentially treating patients with solid tumours, are getting more attention due to their remarkable performance in recognising specific peptides presented by MHC molecules on cancer cell surfaces, thus resulting in mounting attempts to improve their efficacy and clinical applicability. Creative Biolabs manages a sophisticated TCR platform to screen, identify, characterise, optimise, and deliver high-affinity TCR-Jurkat cells and TCR-NK cells.

Immune Cell Products: The Hub

Beyond CAR and TCR cells, Creative Biolabs provides primary and early passage animal cell cultures that support various aspects of immunotherapy research. Their immune cell portfolio includes macrophages, bone marrow, spleen, dendritic cells, and T regulatory cells, each meticulously prepared to ensure high quality and functionality.

"Monitoring the quality of cells is our top priority. Whether you are an academic researcher, an immunologist, or a drug developer, your research depends on the purity, viability, and function of our cells. We take it seriously." Said the scientist.

To learn more about Creative Biolabs' immune cell products, click here.

Recent Issues